Sajid Javid: ...members to bring to their attention a contingent liability the Government has agreed to relating to the two contracts signed between Her Majesty’s Government (HMG) and the medicine supplier Pfizer for the COVID-19 antiviral drug PF-07321332+ritonavir (co-packaged and marketed as Paxlovid). On 20 October 2021, the Government announced the procurement of two novel oral antivirals to treat...
Aaron Bell: ..., I was questioning Susan Hopkins and we were considering vaccine effectiveness. Public Health England had just produced figures showing that the actual effectiveness against hospitalisation of the Pfizer vaccine was 96%, yet the model that we were being asked to rely on for the vote that day said it was 89%. Now, 89 to 96 may not sound like a huge difference, but it is the difference...
Maggie Throup: ...advised that children aged five to 11 years old in a clinical risk group or who are a household contact of someone who is immunosuppressed, should be offered two 10 microgram doses of the Pfizer-BioNTech COVID-19 vaccine, with an interval of eight weeks between the first and second doses. Further advice on the potential merits of COVID-19 vaccination for other five to 11 year olds will be...
Lord Kamall: ...here is that there is no need for parents to contact the NHS; the NHS will make contact with the parents or carers of those eligible. Just to further reassure parents, we will be using a paediatric Pfizer vaccine authorised by the MHRA for use in this age group.
Philippa Whitford: ...to delta, which had four mutations on the spike protein, omicron has 32 mutations. It is a totally different shape. Therefore, sadly with the AstraZeneca vaccine, the key no longer fits the lock. Pfizer does, but it wanes. We need to have broader vaccines so that we might be a bit more resistant to variants in the future. The Government must maintain their support for routine vaccination....
Maggie Throup: I refer back to the fact that the MHRA confirmed that the Pfizer vaccine is safe and effective in 12 to 17-year-olds, and that followed the rigorous review of the safety, quality and effectiveness of the vaccines in this age group. Obviously, the JCVI then made that recommendation, and the CMO has backed it up. It was based on those experts that this decision was made.
George Freeman: Recent analysis supports our understanding that the Pfizer/BioNTech and Moderna vaccines, which are currently being deployed in the UK, appear to work well against the current dominant variants of COVID-19 after a booster-dose. Continuing to administer these vaccines at scale remains essential in our path out of the pandemic. The Government continues to assess our existing vaccine portfolio...
Mike Amesbury: ...Industrial Strategy, what assessment his Department has made of the efficacy of the Valneva covid-19 vaccine; and what steps he is taking to introduce that vaccine for people who cannot take the Pfizer, Astra-Zeneca or Moderna vaccines for ethical reasons.
George Freeman: Recent analysis supports our understanding that the Pfizer/BioNTech and Moderna vaccines, which are currently being deployed in the UK, appear to work well against the current dominant variants of COVID-19 after a booster-dose. Continuing to administer these vaccines at scale remains essential in our path out of the pandemic. The Government continues to assess our existing vaccine portfolio...
Maggie Throup: ...risk group, which includes complex respiratory and neurological conditions, or who were household contacts of someone who is immunosuppressed should be offered two 10 micrograms doses of the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) with an interval of eight weeks between the first and second doses. The minimum interval between any vaccine dose and recent COVID-19 infection should be...
Maggie Throup: ...risk group, which includes complex respiratory and neurological conditions, or who were household contacts of someone who is immunosuppressed should be offered two 10 micrograms doses of the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) with an interval of eight weeks between the first and second doses. The minimum interval between any vaccine dose and recent COVID-19 infection should be...
Lord Bilimoria: ...is the case, can we try to reduce the isolation period as much as possible using testing? Can testing be made free, right up to spring? Finally, given the good news about the MHRA approving the Pfizer antiviral, which in trials has shown an 89% reduction in hospitalisation and deaths, how soon can we get 2.5 million treatments? That will be a game-changer. Will it be before March?
Gareth Thomas: To ask the Secretary of State for Business, Energy and Industrial Strategy, for what reason the Government agreed to (a) keep confidential and (b) hold outside of the UK any dispute with Pfizer on the contract that company holds for producing covid-19 vaccines; and if he will make a statement.
Gareth Thomas: To ask the Secretary of State for Health and Social Care, whether the Pfizer/BioNTech covid-19 vaccine is subject to the 36 month grace period on price controls as outlined in the Voluntary Scheme for Branded Medicines Pricing and Access; and if he will make a statement.
Maggie Throup: The Joint Committee on Vaccination and Immunisation (JCVI) has advised that those eligible for the COVID-19 booster vaccine should be offered a booster dose of either the Pfizer vaccine or the Moderna vaccine. Where mRNA vaccines cannot be offered, vaccination with the AstraZeneca vaccine may be considered for those who received AstraZeneca vaccine in the primary course. There are currently...
Sajid Javid: ...’s Government (HMG) has accepted this advice and all four parts of the UK intend to follow the JCVI’s advice. At this time, the JCVI has advised the following[1]:A two-dose primary course of Pfizer vaccine should be offered to children aged 5 to 11 who are either in an at-risk group as per the UK Health Security Agency’s (UKHSA’s) Green Book or who are a household contact of...
Maggie Throup: .... The UKHSA observed limited waning in vaccine effectiveness against hospitalisation and death more than 20 weeks post-vaccination with Vaxzevria (previously AstraZeneca) or Comirnaty (previously Pfizer) with the Delta variant. Early data suggest vaccine effectiveness is lower against the Omicron variant. However, high levels of protection against symptomatic disease were seen shortly...
Lord Kamall: A service has been in place since 11 October for individuals residing in England who received one or more Pfizer, AstraZeneca, Moderna and Janssen vaccines in the United States of America, the European Union, Iceland, Norway, Liechtenstein, Switzerland, Australia or Canada to record their vaccination in the National Immunisation Management Service (NIMS). If they have received one vaccination...
Gillian Mackay: ...disruption to learning? Has she received an update from the Joint Committee on Vaccination and Immunisation following the Medicines and Healthcare products Regulatory Agency’s approval of the Pfizer vaccine for five to 11-year-olds?
Mark Drakeford: ...doubly vaccinated with the AZ vaccine, as many people in the Senedd will have been, sadly it offers you a very, very low level of protection against the omicron variant. If you get a booster, the Pfizer or Moderna booster, that protection rebounds to up to 75 per cent. So, no vaccine is ever a complete guarantee, but with a booster, you have increased your protection against the omicron...